|
A 61-year-old female patient with non-small cell lung cancer (nsclc) began optune lua therapy on (b)(6) 2025.On july 01, 2026, novocure received a medical record dated june 11, 2026, indicating that the patient experienced significant pruritus and skin irritation.The symptoms were managed with unspecified topical agents and oral hydroxyzine.The patient reported using optune lua therapy for 12 to 15 hours per day; however, due to worsening nocturnal pruritus, she adjusted her device usage schedule to minimize sleep disturbances.The patient was advised to moisturize the affected skin regularly and avoid sun exposure.Additionally, the healthcare provider recommended oral diphenhydramine at bedtime if the pruritus worsened.Attempts were made to contact the prescribing physician; however, no reply was received.
|